TAKC-02 is under clinical development by TAK-Circulator and currently in Phase II for Asthma. According to GlobalData, Phase II drugs for Asthma have a 27% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how TAKC-02’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TAKC-02 is under development for the treatment of steroid-resistant refractory severe asthma. It is administered as inhalational solution. The therapeutic candidate is a gapmer type antisense oligonucleotide which acts by inhibiting MEX3B synthesis.
For a complete picture of TAKC-02’s drug-specific PTSR and LoA scores, buy the report here.